StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$32.52−0.65 (-1.96%)

Close on Nov 19, 2026Market cap $6.72BP/E –Yield –

Immunovant gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Immunovant

Immunovant has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Immunovant figures

See a number that looks wrong?